Medicare Part D a Boon for Drug Companies, House Report Says

U.S. drug manufacturers are reaping a windfall from taxpayers because Medicare’s privately administered prescription drug benefit program pays more than other government programs for the same medicines, a House committee charged in a report.
Los Angeles Times